Dose Response Study of Transdermal Human Insulin in Patients (LEVPS)

A Randomised, Multiple-Dose, Single Period, Phase II/III Dose Response Study to Examine Transdermal Human Insulin in Adult Diabetic Patients

A 21-Day open label study of transdermally delivered human insulin in Type 2 Diabetics as measured by response of down modulation of glucose after dosing of Insulin as compared to historic patient response to injected insulins.

Study Overview

• Status: Not yet recruiting
• Conditions: Glucose, High Blood
• Intervention / Treatment: Biological: Human Insulin; Device: Finger-actuated, Metered Pump Sprayer

Detailed Description

A 21-Day open label study of transdermally delivered human insulin in 30 Type 2 Diabetics is anticipated. Well-managed Type 2 Diabetics will be added to the protocol from the patient census of practicing diabetologists and family practitioners, with preference given to patients already using a wearable Continuous Glucose Monitor (CGM) system. Once added to the protocol, Subjects will be monitored via CGM for two weeks before change of dose form. Subjects will be required to calibrate the CGM against finger-stick blood sampling and to poll the monitor sensor at least every 8 hours during the 42 days of monitoring including the 21-days on-transdermal-dose study period to ensure continuity of interstitial glucose measurement. Subjects will be monitored for 7 days after the last transdermal dose to monitor interchangeability of the dose forms.

Once baseline data is collected, Subjects will exchange transdermal dosing on a Unit for Unit basis. Trial materials will be formulated to a concentration of 100 IUs per mL and dispensed via 0.2 mL metered, finger-actuated pump sprayer, with each pump delivering 20 IUs of Human Insulin to the skin. If a patient, for example is currently using 120 IUs per day, 40 IUs basal insulin and 80 IUs Insulin Aspart, 120 IUs or 6 sprays would be used.

The study nurse will contact each subject every day of the study to answer questions and encourage compliance with the protocol.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Kenneth B. Kirby, BA; Phone Number: 5614296429; Email: KKirby@Langfordresearch.org
• Study Contact Backup: Name: Gordon von Nehring, PhD; Phone Number: 551-580-5978; Email: gordon@langfordresearch.com

Study Locations

• United States
  • Florida
    • Palm Beach Gardens, Florida, United States, 33410
      • Langford Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult Type 2 Diabetes Mellitus ("T2D") Patients on Insulin Replacement therapy not administered via implanted pump well-managing p.r.n as defined by serum glucose ranging between 85 and 200 mg/dL and no more than 1 hypoglycemic or serious hypoglycemic event within the last 9 months.
2. 25 and 75 years of age, inclusive.
3. The subject is willing and able to read and understand the Subject Information Sheet and provide written informed consent.
4. The subject has a body mass index (BMI) within 18-50 kg/m2.
5. The subject is in otherwise good health as determined by medical history and physical examination.
6. The subject's normal insulin dose ranges from between 10 to 200 IU per dose.
7. The subject must agree to continue with daily serum glucose testing by means of a wearable blood glucose monitor for the pharmacodynamic assessments that the investigators have continuous access to via daily downloads.
8. The subject is willing and able to comply with all testing and requirements defined in the protocol.
9. The subject is willing and able to return to the study site for all visits.

Exclusion Criteria:

1. The subject has any relevant deviations from normal other than blood glucose in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator.
2. The subject has had more than 2 hypoglycemic events in the last month.
3. The subject's normal insulin dose is less than 10 and more than 200 IUs.
4. Subjects receiving Insulin from an implanted or external insulin pump system.
5. The subject has had a clinically significant illness or surgical procedure within 30 days preceding entry into this study.
6. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease other than T2D.
7. The subject has a known allergy or history of hypersensitivity to Human Insulin or similar modified Insulin compounds.
8. The subject has used any prescription medication that may interfere with the evaluation of study medication.
9. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and subject's Hemoglobin concentration and hematocrit have not returned to within 5% of normal.
10. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
11. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
12. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Main Experimental; Type 2 Diabetic patients regulating blood glucose with daily injections as basal and/or post-prandial interventions. Patients will receive transdermal product formulated at 100 IU/mL of equivalent International Units of Human Insulin dosed at the same amount as current injected therapies with timing adjusted for the Absorption, Distribution, Metabolism & Elimination (ADME) of human insulin with maximum effect at 3 hours post dose so mid morning before lunch, late afternoon before dinner and before bedtime.

Biological: Human Insulin; International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.; Other Names: Humulin(R); Novolin(R); Device: Finger-actuated, Metered Pump Sprayer; Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Glucose Time in Range for Study Participants	Number of Participants who manage blood glucose in study participants to between 70 and 200 mg Glucose / dL.	21 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Avoidance of Hypoglycemia in Study Participants	Number of study participants that manage blood glucose in study participants to more than 50 mg/dL for 86% of the 21-days-on-dose of the study period	21 days.
Skin Safety in Study Participants	Measure of skin irritation above level 1 - erythema & edema - according to the The Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404, adopted 17th July, 1992: "Acute Dermal Irritation/Corrosion"	21 days dosing plus 7 days post dose follow-up.

Collaborators and Investigators

• Sponsor: Transdermal Delivery Solutions Corp
• Collaborators: Langford Research Institute, Inc.
• Investigators: Principal Investigator: Chandan A.S. Alam, MD, Langford Research Institute

Study record dates

Study Major Dates

• Study Start (Estimated): September 2, 2027
• Primary Completion (Estimated): October 15, 2027
• Study Completion (Estimated): December 15, 2027

Study Registration Dates

• First Submitted: December 1, 2021
• First Submitted That Met QC Criteria: December 1, 2021
• First Posted (Actual): December 16, 2021

Study Record Updates

• Last Update Posted (Actual): May 26, 2026
• Last Update Submitted That Met QC Criteria: May 21, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptide Hormones; Peptides; Amino Acids, Peptides, and Proteins; Insulins; Pancreatic Hormones; Proinsulin; Insulin
• Other Study ID Numbers: LEV201-D-120121

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes